Last reviewed · How we verify
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease. Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period following the last dose of study treatment. For the first approximately 20 participants effect of food will be evaluated on the Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.
Details
| Lead sponsor | NodThera Limited |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 67 |
| Start date | Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Apr 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Cardiovascular Diseases
Interventions
- NT-0796
Countries
United States